<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574493</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2018-03 ORE</org_study_id>
    <nct_id>NCT03574493</nct_id>
  </id_info>
  <brief_title>Rectal Surgery Evaluation Trial (RESET)</brief_title>
  <acronym>RESET</acronym>
  <official_title>Rectal Surgery Evaluation Trial (RESET): Laparotomy vs Laparoscopy vs Robotic vs TaTME Rectal Surgery Matched Parallel Cohort Trial for High Surgical Risk Cancer Patients, With Mid- to Low Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intuitive Surgical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total mesorectal excision (TME) is the standard of care for rectal cancer, which can be
      combined with low anterior resection (LAR) in patients with mid-to-low rectal cancer. The
      narrow pelvic space and difficulties in obtaining adequate exposure make surgeries
      technically challenging. Four techniques are used to perform the surgery: open laparotomy,
      laparoscopy, robot-assisted surgery, and transanal surgery. Comparative data for these
      techniques is required to provide clinical data on the surgical management of rectal cancers
      by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Rectal Surgery Evaluation Trial will be a prospective, observational, case-matched,
      four-cohort, multicenter trial designed to study TME with LAR using open laparotomy,
      laparoscopy, robot-assisted surgery, or transanal surgery in high-surgical-risk patients with
      mid-to-low, non-metastatic rectal cancer. All surgeries will be performed by surgeons
      experienced in a technique. Oncologic, morbidity and functional outcomes will be assessed in
      a composite primary outcome, with success defined as circumferential resection margin ≥1 mm,
      TME grade III, and minimal postoperative morbidity (absence of Clavien-Dindo grade III-IV
      complications within 30 days after surgery). Secondary endpoints will include the co-primary
      endpoints over the long-term (2 years), quality of surgery, quality of life, length of
      hospital stay, operative time, and rate of unplanned conversions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Efficacy of surgical method (success determined by composite of Oncologic, morbidity and functional outcomes)</measure>
    <time_frame>up to 4 years</time_frame>
    <description>CRM, TME grade III, The absence of clavien dindo grade III-IV complications within 30 days post op</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Open laparotomy</arm_group_label>
    <description>A surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic surgery</arm_group_label>
    <description>A minimally-invasive technique in which operations are performed via small incisions (usually 0.5-1.5 cm) at a location distant to the site of interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Robot-assisted surgery using the da Vinci® Surgical System</arm_group_label>
    <description>A minimally-invasive approach that allows good precision, flexibility, and control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transanal surgery through the anus</arm_group_label>
    <description>Where the protectomy is performed down to up until the Douglas pouch</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME with LAR</intervention_name>
    <description>Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME</description>
    <arm_group_label>Laparoscopic surgery</arm_group_label>
    <arm_group_label>Open laparotomy</arm_group_label>
    <arm_group_label>Robot-assisted surgery using the da Vinci® Surgical System</arm_group_label>
    <arm_group_label>Transanal surgery through the anus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        high- risk patients with mid-to-low rectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. Rectal adenocarcinoma from middle and lower third (less than 10 cm from the anal
             verge) with a sphincter saving procedure

          3. High risk operative patients (two of these factors as assessed on MRI):

               1. Obese patient with a BMI &gt; 30 (male or female)

               2. Narrow pelvis: inter-tuberous distance &lt; 10 cm

               3. Large tumoral volume with suspicion of close predictive margin (CRM ≤ 1 mm) at
                  diagnosis

               4. Expected coloanal or ultra-low colorectal anastomosis

          4. Patients with adequate performance status (Eastern Cooperative Oncology Group Scale
             score of ≤2)

          5. Patient has signed and dated the informed consent before inclusion in the study.

        Exclusion Criteria:

          1. Patient with a comorbid illness or condition that would preclude the use of surgery.

          2. Patients with T4b tumors which impose a pelvectomy

          3. Patient requires an abdominal perineal resection (APR)

          4. Patients with concurrent or previous invasive pelvic malignant tumors (cervical,
             uterine, or rectal; excluding the prostate) within 5 years before study enrollment

          5. Patient undergoing emergency procedures

          6. Planned rectal surgery along with major concomitant procedures (e.g. hepatectomies,
             other intestinal resections)

          7. Metastatic disease

          8. Pregnant or suspected pregnancy

          9. Patients unwilling to comply with all follow-up study requirements

         10. Patient included in another study which impact on the surgical technique or its
             choice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe ROUANET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Bleuse, MD</last_name>
    <phone>+33467613102</phone>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Rouanet, MD, PhD</last_name>
      <phone>04-67-61-3071</phone>
      <email>prouanet@valdorel.fnclcc.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Hompes R, Guy R, Jones O, Lindsey I, Mortensen N, Cunningham C. Transanal total mesorectal excision with a side-to-end stapled anastomosis - a video vignette. Colorectal Dis. 2014 Jul;16(7):567. doi: 10.1111/codi.12660.</citation>
    <PMID>24801986</PMID>
  </results_reference>
  <results_reference>
    <citation>MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993 Feb 20;341(8843):457-60.</citation>
    <PMID>8094488</PMID>
  </results_reference>
  <results_reference>
    <citation>Buchs NC, Nicholson GA, Ris F, Mortensen NJ, Hompes R. Transanal total mesorectal excision: A valid option for rectal cancer? World J Gastroenterol. 2015 Nov 7;21(41):11700-8. doi: 10.3748/wjg.v21.i41.11700. Review.</citation>
    <PMID>26556997</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun Z, Kim J, Adam MA, Nussbaum DP, Speicher PJ, Mantyh CR, Migaly J. Minimally Invasive Versus Open Low Anterior Resection: Equivalent Survival in a National Analysis of 14,033 Patients With Rectal Cancer. Ann Surg. 2016 Jun;263(6):1152-8. doi: 10.1097/SLA.0000000000001388.</citation>
    <PMID>26501702</PMID>
  </results_reference>
  <results_reference>
    <citation>Vennix S, Pelzers L, Bouvy N, Beets GL, Pierie JP, Wiggers T, Breukink S. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev. 2014 Apr 15;(4):CD005200. doi: 10.1002/14651858.CD005200.pub3. Review.</citation>
    <PMID>24737031</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ; COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013 Mar;14(3):210-8. doi: 10.1016/S1470-2045(13)70016-0. Epub 2013 Feb 6.</citation>
    <PMID>23395398</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee SH, Lim S, Kim JH, Lee KY. Robotic versus conventional laparoscopic surgery for rectal cancer: systematic review and meta-analysis. Ann Surg Treat Res. 2015 Oct;89(4):190-201. doi: 10.4174/astr.2015.89.4.190. Epub 2015 Sep 25.</citation>
    <PMID>26448918</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun Y, Xu H, Li Z, Han J, Song W, Wang J, Xu Z. Robotic versus laparoscopic low anterior resection for rectal cancer: a meta-analysis. World J Surg Oncol. 2016 Mar 1;14:61. doi: 10.1186/s12957-016-0816-6.</citation>
    <PMID>26928124</PMID>
  </results_reference>
  <results_reference>
    <citation>Trastulli S, Farinella E, Cirocchi R, Cavaliere D, Avenia N, Sciannameo F, Gullà N, Noya G, Boselli C. Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. Colorectal Dis. 2012 Apr;14(4):e134-56. doi: 10.1111/j.1463-1318.2011.02907.x. Review.</citation>
    <PMID>22151033</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H, Ma Y. Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: a meta-analysis. Ann Surg Oncol. 2012 Nov;19(12):3727-36. doi: 10.1245/s10434-012-2429-9. Epub 2012 Jul 3.</citation>
    <PMID>22752371</PMID>
  </results_reference>
  <results_reference>
    <citation>Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Rautio T, Thomassen N, Tilney H, Gudgeon M, Bianchi PP, Edlin R, Hulme C, Brown J. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. JAMA. 2017 Oct 24;318(16):1569-1580. doi: 10.1001/jama.2017.7219.</citation>
    <PMID>29067426</PMID>
  </results_reference>
  <results_reference>
    <citation>Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, Moran B, Hanna GB, Mortensen NJ, Tekkis PP; TaTME Registry Collaborative. Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases. Ann Surg. 2017 Jul;266(1):111-117. doi: 10.1097/SLA.0000000000001948.</citation>
    <PMID>27735827</PMID>
  </results_reference>
  <results_reference>
    <citation>Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Davies L, Wilson K, Hague W, Simes J; ALaCaRT Investigators. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. JAMA. 2015 Oct 6;314(13):1356-63. doi: 10.1001/jama.2015.12009.</citation>
    <PMID>26441180</PMID>
  </results_reference>
  <results_reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </results_reference>
  <results_reference>
    <citation>Baik SH, Kwon HY, Kim JS, Hur H, Sohn SK, Cho CH, Kim H. Robotic versus laparoscopic low anterior resection of rectal cancer: short-term outcome of a prospective comparative study. Ann Surg Oncol. 2009 Jun;16(6):1480-7. doi: 10.1245/s10434-009-0435-3. Epub 2009 Mar 17.</citation>
    <PMID>19290486</PMID>
  </results_reference>
  <results_reference>
    <citation>Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Posner M, Read T, Monson J, Wren SM, Pisters PW, Nelson H. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA. 2015 Oct 6;314(13):1346-55. doi: 10.1001/jama.2015.10529.</citation>
    <PMID>26441179</PMID>
  </results_reference>
  <results_reference>
    <citation>Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, Minsky BD, Wong WD, Guillem JG. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. J Am Coll Surg. 2005 Jun;200(6):876-82; discussion 882-4.</citation>
    <PMID>15922198</PMID>
  </results_reference>
  <results_reference>
    <citation>Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009 Mar 7;373(9666):811-20. doi: 10.1016/S0140-6736(09)60484-0.</citation>
    <PMID>19269519</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, Chang HJ, Lee HS, Kim SY, Jung KH, Hong YS, Kim JH, Sohn DK, Kim DH, Oh JH. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol. 2010 Jul;11(7):637-45. doi: 10.1016/S1470-2045(10)70131-5. Epub 2010 Jun 16.</citation>
    <PMID>20610322</PMID>
  </results_reference>
  <results_reference>
    <citation>D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998 Oct 15;17(19):2265-81.</citation>
    <PMID>9802183</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>laparotomy</keyword>
  <keyword>laparoscopy</keyword>
  <keyword>low anterior resection</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>robot assisted surgery</keyword>
  <keyword>total mesorectal excision</keyword>
  <keyword>transanal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

